IN a groundbreaking development, the Cuban Ambassador to Guyana, Jorge Francisco Soberón Luis, revealed that Cuba has successfully registered the world’s first therapeutic vaccine against advanced lung cancer.
Known as CIMAVAX-EGF, the vaccine has already been administered to more than 1,000 patients within the country, marking a significant stride in the field of oncology.

The Cuban envoy explained that the vaccine developed by experts from the Center for Molecular Immunology (CIM), the CIMAVAX-EGF vaccine, is designed to transform advanced lung cancer into a controllable chronic disease. This milestone comes after more than 15 years of dedicated research by Cuban scientists.

The vaccine, he noted, specifically targets the tumor-related system without causing severe adverse effects, offering a promising avenue for cancer patients. Administered following the completion of radio or chemotherapy treatments, CIMAVAX-EGF aids in controlling tumor growth without associated toxicity.

He explained that one of the key features of the vaccine is its basis in a protein related to skin growth factor, intricately linked to cell proliferation processes. This innovative approach sets it apart from traditional cancer treatments, providing a unique and effective solution.

Moreover, CIMAVAX-EGF can serve as a chronic treatment, significantly enhancing both the life expectancy and quality of life for patients. The success of the vaccine has prompted its administration in other countries, showcasing the global potential of Cuban medical advancements.

Beyond its application in lung cancer, there are ongoing evaluations exploring the use of CIMAVAX-EGF principles in therapies against various tumors, including prostate, uterus, and breast tumors. This suggests a broader impact on cancer treatment methodologies and opens new possibilities for patients facing different forms of the disease.

The collaboration between the Cuban institution and the Roswell Park Cancer Research Centre in the United States has played a pivotal role in the development and dissemination of this groundbreaking drug. The alliance signifies a commitment to international cooperation in advancing medical research and developing innovative solutions for global health challenges.

Ambassador Soberón Luis expressed pride in Cuba’s scientific achievements and emphasised the potential of CIMAVAX-EGF to revolutionise cancer treatment globally. The diplomatic ties between Cuba and other nations, including the ongoing collaboration with the United States, underscore the importance of shared efforts in addressing critical healthcare issues and advancing medical science.